4/A: Inmune Bio Executive Lowdell Acquires Shares and Warrants in Direct Offering

Mark William Lowdell, Chief Scientific Officer of Inmune Bio, Inc., purchased shares and warrants in a registered direct offering, increasing his holdings in the company.

Summary

• Mark William Lowdell, Chief Scientific Officer of Inmune Bio, Inc., filed an amended Form 4 to report a purchase of common stock and warrants.
• The original filing on April 23, 2024, incorrectly identified the transaction as an award, but this amendment corrects it to reflect a purchase.
• On April 19, 2024, Lowdell acquired 14,423 shares of common stock at $8.32 per share and warrants to purchase 14,423 shares at $0.125 per warrant.
• The purchase was part of a registered direct offering at a price of $8.445, with an aggregate purchase price of $121,802.24.
• Following the transaction, Lowdell directly owns 1,510,806 shares of Inmune Bio, Inc.
• The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the 'Termination Date').
• Directors, officers or other affiliates of the Company will have an additional 60 days from the termination of the blackout date to exercise the Warrant if the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchase by an executive is generally a good sign, but the warrant terms introduce some uncertainty.

Positives

• The purchase by a key executive could be seen as a positive signal about the company's prospects.
• Lowdell's increased stake aligns his interests with those of other shareholders.

Risks

• The warrants have a limited exercise window, tied to the reporting of top-line data from the Phase 2 Alzheimer's program, which introduces uncertainty.
• Blackout periods could further restrict the exercise window for officers, directors, or affiliates.

Future Outlook

The warrants' exercisability is contingent on the timing of top-line data reporting from the Phase 2 Alzheimer's program, making future actions dependent on clinical trial outcomes.

Industry Context

Executive stock purchases are common in the biotech industry and are often viewed as a sign of confidence in the company's future prospects, particularly concerning ongoing clinical trials.

Stakeholder Impact

• Shareholders may view the executive's purchase as a positive signal.
• The outcome of the Phase 2 Alzheimer's program will significantly impact shareholder value.

Next Steps

• Lowdell may exercise the warrants depending on the outcome of the Phase 2 Alzheimer's program and the timing of top-line data reporting.
• The company will likely report top-line data from the Phase 2 Alzheimer's program, which will impact the warrants' value.

Key Dates